000			01955 a2200529 4500
005			20250517072846.0
264		0	_c20160614
008			201606s 0 0 eng d
022			_a1535-5667
024	7		_a10.2967/jnumed.115.161752 _2doi
040			_aNLM _beng _cNLM
100	1		_aModak, Shakeel
245	0	0	_aArsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. _h[electronic resource]
260			_bJournal of nuclear medicine : official publication, Society of Nuclear Medicine _cFeb 2016
300			_a231-7 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
650	0	4	_a3-Iodobenzylguanidine _xadverse effects
650	0	4	_aAdolescent
650	0	4	_aAdrenal Gland Neoplasms _xradiotherapy
650	0	4	_aAdult
650	0	4	_aArsenic Trioxide
650	0	4	_aArsenicals _xadverse effects
650	0	4	_aBrain Neoplasms _xradiotherapy
650	0	4	_aChild
650	0	4	_aChild, Preschool
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aNeuroblastoma _xradiotherapy
650	0	4	_aOxides _xadverse effects
650	0	4	_aParaganglioma _xradiotherapy
650	0	4	_aPheochromocytoma _xradiotherapy
650	0	4	_aRadiation-Sensitizing Agents _xadverse effects
650	0	4	_aRadiopharmaceuticals _xadverse effects
650	0	4	_aSurvival Analysis
650	0	4	_aTreatment Outcome
700	1		_aZanzonico, Pat
700	1		_aCarrasquillo, Jorge A
700	1		_aKushner, Brian H
700	1		_aKramer, Kim
700	1		_aCheung, Nai-Kong V
700	1		_aLarson, Steven M
700	1		_aPandit-Taskar, Neeta
773	0		_tJournal of nuclear medicine : official publication, Society of Nuclear Medicine _gvol. 57 _gno. 2 _gp. 231-7
856	4	0	_uhttps://doi.org/10.2967/jnumed.115.161752 _zAvailable from publisher's website
999			_c25609751 _d25609751